Guiding NOAC therapy for patients with acute coronary syndrome after heart procedures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the effectiveness and safety of a short-term triple antithrombotic therapy, which includes DAPT and low-dose rivaroxaban, against standard DAPT in patients with acute coronary syndrome (ACS) who are at high ischemic risk. Participants will be randomly assigned to receive either the novel therapy for three months followed by standard DAPT or standard DAPT throughout the study. The trial will assess whether the new approach can reduce ischemic events without increasing the risk of severe bleeding. Patients will undergo five follow-up assessments during the study period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with Acute Coronary Syndrome 1-7 days after initial symptom stabilization,
* Aged 18-75 years old,
* Elevated D-dimer levels (≥0.28 μg/ml) on admission or PARIS coronary thrombosis risk score ≥ 3 points,
* Received Percutaneous Coronary Intervention and not on non-oral anticoagulants,
* Indicated for dual antiplatelet medication

Exclusion Criteria:

* Platelet level below 90 x10\^6
* Hemoglobin level is less than 11g/dL
* History of severe bleeding
* History of stroke/TIA
* Severe hepatic/renal insufficiency
* Indicated for anticoagulation

Where it's running

• Chinese Academy of Medical Sciences, Fuwai Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Jinqing Yuan, MD — Chinese Academy of Medical Sciences, Fuwai Hospital
• Study coordinator: Jinqing Yuan, MD
• Email: dr_jinqingyuan@sina.com
• Phone: +86-10-68314466

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry collecting data on patients undergoing heart artery procedures

  This study is collecting information from patients who are having heart artery procedures to see how they do during and after their treatment.

  Recruiting Federico II University · Naples · NCT05248165

• Comparing a new medication to standard treatment for preventing stomach issues in heart patients on blood thinners

  This study is testing a new medication called tegoprazan to see if it can prevent stomach problems just as well as the standard treatment for heart patients who are taking blood thinners.

  Recruiting at 36 sites Phase 4 Asan Medical Center · Anyang and 44 other locations · NCT04416581

• Registry for patients undergoing angioplasty in Korea

  This study is collecting information from patients who have had angioplasty to help understand how well the treatment works in real life.

  Recruiting Yonsei University · Seoul · NCT03908463

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• What affects bleeding control and how long you need to lie flat after femoral arterial sheath removal

  We will see if patient and procedure factors can predict how long ICU patients need compression and bed rest after femoral arterial sheath removal to prevent bleeding and hematoma.

  Recruiting National Taiwan University Hospital · Taipei · NCT07469397

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.